Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.03
-0.1750-5.47%
Volume:520.35K
Turnover:1.61M
Market Cap:289.19M
PE:-2.51
High:3.20
Open:3.20
Low:3.03
Close:3.20
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:0.43
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:0.95
PE(LYR):-0.77

Loading ...

Centene Appoints Cressey’s Paul Diaz to Board as Burdick Retires

Reuters
·
Jul 28

Myriad Genetics Schedules Q2 Earnings Conference Call

Reuters
·
Jul 23

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

GlobeNewswire
·
Jul 23

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

GlobeNewswire
·
Jul 21

Myriad Says Meta-analysis Supports Prognostic Performance of Prolaris Biopsy Test in Localized Prostate Cancer

Reuters
·
Jul 02

Sera Prognostics Names Former Myriad Genetics CEO Mark Capone to Board

Reuters
·
Jul 01

Myriad Genetics Announces Resignation of Board Member Skovronsky

TIPRANKS
·
Jun 23

Myriad Genetics says MONITOR-Breast study supports Precise MRD ctDNA test in neoadjuvant monitoring

Reuters
·
Jun 23

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

GlobeNewswire
·
Jun 23

Myriad Genetics director Daniel Skovronsky resigns from board

Reuters
·
Jun 23

3 Penny Stocks With Market Caps Over $400M To Consider

Simply Wall St.
·
Jun 22

Living Longer Is Big Business. These Stocks Will Benefit. -- Barrons.com

Dow Jones
·
Jun 19

Myriad Genetics director Rashmi Kumar sells 15,000 shares worth $66,843

Reuters
·
Jun 10

Myriad Genetics Holds 2026 Annual Meeting and Approves Plans

TIPRANKS
·
Jun 05

Myriad Genetics shareholders approve 4 million-share increase to employee stock purchase plan

Reuters
·
Jun 05

Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Dow Jones
·
Jun 02

Myriad Genetics reports interim MONSTAR-SCREEN-3 data showing Precise MRD test prognostic value across cancers at ASCO 2026

Reuters
·
May 27

Myriad Genetics launches Prolaris + AI prostate cancer test combining genomics, digital pathology AI

Reuters
·
May 27

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

THOMSON REUTERS
·
May 27

MindWalk Holdings Leads Our Trio Of Promising Penny Stocks

Simply Wall St.
·
May 23